ICH GCP E6(R3) Update: A New Step Forward in Protecting Clinical Trial Participants

Clinical trials are continuously evolving to keep pace with advances in medicine and technology. Today, many studies incorporate telemedicine visits, electronic consent, wearable health monitoring devices, and remote data collection. In this context, international guidelines must also be regularly updated to uphold a core principle: participants must always remain at the center, with their rights, safety, and well-being fully protected.

ICH GCP (International Council for Harmonisation – Good Clinical Practice) is the global standard for conducting clinical trials, ensuring they are performed ethically, accurately, transparently, and safely, with participant welfare as the top priority. The ICH GCP E6(R3) version represents the most significant update since R2 (2016), clearly reflecting a shift toward risk-based management and the expanded use of digital technologies in clinical research.

1. What’sNew in E6(R3)? 

Risk- and Quality-Based Study Design

From the design stage, research teams are required to identify factors that may directly impact participant safety or compromise data integrity. Control measures are then focused on these critical elements, reducing unnecessary administrative burden while enhancing both participant protection and scientific value.

Flexible, Risk-Proportionate Monitoring

Rather than relying solely on on-site monitoring, E6(R3) encourages a combination of centralized monitoring, remote oversight, and the use of electronic data. This flexible approach enables sponsors and research sites to allocate resources more efficiently while maintaining rigorous oversight of safety and data quality.

Recognition of Digital Technologies

The updated guideline formally acknowledges approaches such as electronic informed consent (eConsent), electronic data capture, and decentralized clinical trials. These innovations are permitted provided that participant safety, data privacy, medical oversight, and compliance with local regulations are fully ensured.

Clearer, More Practical Structure

E6(R3) is organized into:

• Core Principles applicable to all clinical trials

• Annex 1 for traditional site-based trials

• Annex 2 (under development) for more complex and innovative trial designs

This structure helps stakeholders clearly determine applicability and implement the guidelines appropriately for different tyes of studies.

2. How Do Participants Benefit? 

Enhanced Safety

Key risks—such as serious adverse events, medication errors, or delays in care must be identified early, with proactive risk management plans in place. This leads to more effective systems for detecting, reporting, and managing adverse events, thereby reducing risks to participants.

Greater Transparency

Study information may be delivered in person or through digital platforms, but it must ensure that participants fully understand the study purpose, potential benefits and risks, their right to refuse or withdraw at any time, and how to seek support when needed.

Improved Convenience

With decentralized elements, participants may be monitored at home or at nearby healthcare facilities while still meeting GCP standards. This reduces travel burden—especially for elderly individuals, those with chronic conditions, or those living far from major hospitals.

More Respectful Participant Experience

E6(R3) emphasizes the “burden of participation,” including visit frequency, waiting time, number of tests, and required documentation. Well-designed studies take these factors into account, resulting in more reasonable schedules, clearer materials, and better communication channels for participants.

Clinical trials provide early access to promising new therapies while enabling participants to contribute to medical progress and expand future treatment options for the wider community. With ICH GCP E6(R3), participants are better protected, better informed, and more clearly recognized as central to the research process.

Vinmec – VinUni is committed to conducting high quality clinical trials that are safe, transparent, and fully compliant with ICH GCP standards. We place participants at the center of every study, ensuring their rights and safety are upheld throughout the research journey.

If you or your loved ones are considering participation in a clinical trial, please contact the Vinmec – VinUni research team for detailed guidance and dedicated support.

REFERENCES

1. ICH Good Clinical Practice E6(R3). Available at: https://database.ich.org/